These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18460266)

  • 1. Compliance and persistence with osteoporosis therapies.
    Silverman SL; Gold DT
    Curr Rheumatol Rep; 2008 Apr; 10(2):118-22. PubMed ID: 18460266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
    Emkey RD; Ettinger M
    Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of persistence and compliance with bisphosphonates for osteoporosis.
    Cramer JA; Gold DT; Silverman SL; Lewiecki EM
    Osteoporos Int; 2007 Aug; 18(8):1023-31. PubMed ID: 17308956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of patient training on persistence, compliance, and tolerability of different dosing frequency regimens of bisphosphonate therapy: An observational study in Turkish patients with postmenopausal osteoporosis.
    Akarırmak Ü; Koçyiğit H; Eskiyurt N; Esmaeilzadeh S; Kuru Ö; Yalçinkaya EY; Peker Ö; Ekim AA; Özgirgin N; Çalış M; Rezvani A; Çevikol A; Eyigör S; Şendur ÖF; İrdesel J;
    Acta Orthop Traumatol Turc; 2016 Aug; 50(4):415-23. PubMed ID: 27524671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in persistence among different weekly oral bisphosphonate medications.
    Sheehy O; Kindundu CM; Barbeau M; LeLorier J
    Osteoporos Int; 2009 Aug; 20(8):1369-76. PubMed ID: 19020921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
    Okazaki R
    Clin Calcium; 2009 Jan; 19(1):30-6. PubMed ID: 19122262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem.
    Cramer JA; Silverman S
    Am J Med; 2006 Apr; 119(4 Suppl 1):S12-7. PubMed ID: 16563936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there an advantage to an injected bisphosphonate versus a daily or monthly oral regimen?
    Mayo Clin Womens Healthsource; 2008 Sep; 12(9):8. PubMed ID: 18667976
    [No Abstract]   [Full Text] [Related]  

  • 9. Factors contributing to compliance with osteoporosis medication.
    Kertes J; Dushenat M; Vesterman JL; Lemberger J; Bregman J; Friedman N
    Isr Med Assoc J; 2008 Mar; 10(3):207-13. PubMed ID: 18494234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral bisphosphonate compliance and persistence: a matter of choice?
    Silverman SL; Schousboe JT; Gold DT
    Osteoporos Int; 2011 Jan; 22(1):21-6. PubMed ID: 20458571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women.
    Sambrook P
    Clin Interv Aging; 2007; 2(1):65-72. PubMed ID: 18044076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
    Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
    Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization.
    Sunyecz JA; Mucha L; Baser O; Barr CE; Amonkar MM
    Osteoporos Int; 2008 Oct; 19(10):1421-9. PubMed ID: 18351427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ibandronate].
    Tobinai M
    Clin Calcium; 2011 Jan; 21(1):79-86. PubMed ID: 21187598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Considerations regarding adherence of anti-osteoporosis therapy.
    Lagari VS; McAninch E; Baim S
    Postgrad Med; 2015 Jan; 127(1):92-8. PubMed ID: 25526234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is a 'failure' of bisphosphonate therapy for osteoporosis?
    Carey JJ
    Cleve Clin J Med; 2005 Nov; 72(11):1033-9. PubMed ID: 16315442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compliance with drug therapy for postmenopausal osteoporosis.
    Weycker D; Macarios D; Edelsberg J; Oster G
    Osteoporos Int; 2006; 17(11):1645-52. PubMed ID: 16862397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonate therapy: how long is long enough?
    McClung MR
    Osteoporos Int; 2015 May; 26(5):1455-7. PubMed ID: 25609156
    [No Abstract]   [Full Text] [Related]  

  • 19. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
    Epstein S; Jeglitsch M; McCloskey E
    Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence with intravenous zoledronate in elderly patients with osteoporosis.
    Lee YK; Nho JH; Ha YC; Koo KH
    Osteoporos Int; 2012 Sep; 23(9):2329-33. PubMed ID: 22179417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.